Cargando…

Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors

SIMPLE SUMMARY: Children with metastatic or relapsed solid tumors remain in desperate need of better treatment since conventional chemotherapy is often ineffective and can cause long-term complications. Precision oncology offers the possibility of less toxic and more beneficial treatment through the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellantoni, Andrew J., Wagner, Lars M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303693/ https://www.ncbi.nlm.nih.gov/pubmed/34298746 http://dx.doi.org/10.3390/cancers13143531

Ejemplares similares

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
por: Huang, Liling, et al.
Publicado: (2020)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?
por: Aveic, Sanja, et al.
Publicado: (2016)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
por: Montor, Wagner Ricardo, et al.
Publicado: (2018)

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
por: Albarrán, Víctor, et al.
Publicado: (2022)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Genomics-Driven Precision Medicine in Pediatric Solid Tumors
por: Suthapot, Praewa, et al.
Publicado: (2023)

Targeted treatment of solid tumors in pediatric precision oncology
por: Bertacca, Ilaria, et al.
Publicado: (2023)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

The Role of PIM Kinases in Pediatric Solid Tumors
por: Julson, Janet Rae, et al.
Publicado: (2022)

More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds
por: Vergoulidou, Maria
Publicado: (2015)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
por: Nakamichi, Shinji, et al.
Publicado: (2015)

LEP pursues Higgs boson and greater W precision
Publicado: (1999)

LEP pursues Higgs boson and greater W precision
por: Clare, B
Publicado: (1999)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
por: Wagner, Lars M, et al.
Publicado: (2017)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
por: Assi, Ahmad, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells
por: Krchniakova, Maria, et al.
Publicado: (2022)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Tyrosine Kinase Receptors in Oncology
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2020)

Role of Actionable Genes in Pursuing a True Approach of Precision Medicine in Monogenic Diabetes
por: Marucci, Antonella, et al.
Publicado: (2022)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Prognostic value of spleen tyrosine kinase in human solid tumors
por: Ni, Beibei, et al.
Publicado: (2018)

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
por: Qu, Kai, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
por: Yang, Sei-Hoon
Publicado: (2013)

Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
por: Park, Hyunjung, et al.
Publicado: (2022)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor
por: Coelho, Yasmin Nascimento Bernardes, et al.
Publicado: (2023)

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
por: Nagano, Tatsuya, et al.
Publicado: (2018)

Proteolytic Cleavage of Receptor Tyrosine Kinases
por: Huang, Hao
Publicado: (2021)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1j31b981smu1n2cl9lqcu2ji7f